Clinical Research Directory

Inclusion Criteria: * Subjects scheduled for eligibility screening at the study site * Female or Male sex * Subjects with acne prone skin or skin with scar from acne * Subjects exposed to sunlight for at least 4 hours a day * Signing the informed consent form written by the investigators * Certifying not taking part in another clinical study that could interfere with the current one * Affirming the truth of the personal information declared to the technical staff * Capable of following directions and reliable to respect the constraints of the protocol * Free to ensure the visits to the Research Lab * Subjects with self-perceived * Subjects may have mild to sensitive and stressed skin Exclusion Criteria: * Female subjects who are pregnant, breastfeeding, or planning a pregnancy * Subjects with severe overall photodamage as determined by the Investigator. * Subjects who have any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin, including rosacea, acne, and excessively oily or dry skin. * Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products. * Subjects' use of any medications that are known to potentially cause changes in the facial skin as determined by the Investigator. * Subjects who spend excessive time out in the sun. * Subjects who are unwilling or unable to comply with the requirements of the protocol. * Subjects deprived of freedom by administrative or legal decision or under guardianship * Subjects planning hospitalization during the study * Subjectsaving received vaccination within 2 weeks before the study or intending to be vaccinated during the study * Subjects with diseases in the period immediately preceding the current study under treatment topically or systemically with any drug that may affect the outcome of the test, particularly: systemic retinoids within 6 months, topical retinoids within 2 months anti-inflammatory or antihistamine products within the 2 weeks antibiotics within 2 weeks medication for malignancy (of any kind) within 5 years desensitization treatment within 6 months * Subjects in treatments with topical products based on alpha and beta-hydroxy acids in the 45 days before the start of the study * Subjects reactive to sun/having photosensitivity.